Form 4: Xencor CEO Bassil Dahiyat Reports Stock and Option Transactions

Bassil Dahiyat, CEO of Xencor, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• Bassil I. Dahiyat, the President and CEO of Xencor, Inc., filed a Form 4 on March 5, 2025, reporting transactions related to Xencor's common stock.
• On March 4, 2025, Dahiyat acquired 109,745 shares of common stock and disposed of 485,135 shares.
• Dahiyat also acquired options to purchase 329,236 shares of common stock at an exercise price of $14.15, exercisable starting March 4, 2026, and expiring on March 4, 2035.
• Following these transactions, Dahiyat directly owns 329,236 derivative securities.
• A power of attorney was executed on February 19, 2025, granting Bassil I. Dahiyat, Bart Jan Cornelissen, and Celia E. Eckert the authority to execute Forms 3, 4, 5, and 144 on behalf of the reporting person.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine filing of insider transactions. The disposal of shares could be a slight negative, but without more context, it's difficult to assess the impact.

Positives

• The acquisition of restricted stock units and stock options could align the CEO's interests with those of the shareholders.
• The vesting schedule for the stock options incentivizes long-term performance.

Negatives

• The disposal of 485,135 shares of common stock by the CEO could be perceived negatively by investors.

Risks

• The disposal of a large number of shares by the CEO could indicate a lack of confidence in the company's future prospects, although this is not explicitly stated.
• Market conditions and company performance could affect the value of the stock options and restricted stock units.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The information is relevant to investors tracking insider sentiment and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.
• Vesting schedules, such as the one described in the document, are typical for these types of equity grants.
• Comparing the size of the stock option grant and the number of shares disposed of to those of peer companies (e.g., Amgen, Regeneron) would provide a better understanding of the magnitude of these transactions.

Stakeholder Impact

• Shareholders may be interested in the CEO's transactions as an indicator of confidence in the company.
• Employees may be affected by the vesting schedules of the stock options and restricted stock units.

Key Dates